Completed PHASE4 INTERVENTIONAL 2-arm NCT00127270

Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder

Using Behavioral Therapy in Combination With Drug-Darifenacin for Symptoms of Overactive Bladder

Sponsor: Novartis

Interventions Behavioral therapy Darifenacin

Updated 6 times since 2017 Last updated: Jan 23, 2008 Started: May 31, 2005 Completion: Feb 28, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Urinary Incontinence, this trial is completed. The trial is conducted by Novartis and has accumulated 6 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

May 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis
Procter and Gamble

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alpharetta, United States , Atlanta, United States , Aurora, United States , Aventura, United States , Birmingham, United States , Centerville, United States , Columbia, United States , Concord, United States , Corsicana, United States , Culver City, United States and 51 more locations